Designing Intelligence for Drug Development Programmes

In drug development, model quality is constrained by programme design. Fragmented biological and chemistry datasets, inconsistent annotations, and disconnected workflows often create larger failure modes than the choice of model architecture.

The practical shift is to treat intelligence as programme infrastructure: data standards, validation routines, decision checkpoints, and feedback loops that improve model behaviour as programmes progress.

This is where AI systems become durable. Instead of isolated model outputs, teams gain continuously improving decision support grounded in translational and regulatory realities.